menu
    • menu
    [{"orgOrder":0,"company":"ELPEN Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GREECE","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"HARS","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"ELPEN Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ELPEN Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ELPEN Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"ELPEN Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GREECE","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Esomeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"ELPEN Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ELPEN Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"ELPEN Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"ELPEN Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GREECE","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ranolazine","moa":"Sodium channel protein type V alpha subunit | Sodium channel protein type IV alpha subunit","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"ELPEN Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ELPEN Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"ELPEN Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"ELPEN Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GREECE","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"ELPEN Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ELPEN Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ELPEN Pharmaceutical \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by ELPEN Pharmaceutical

    Menu

    ELPEN Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ELPEN Pharmaceutical

                            Greece arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            ELPEN Pharmaceutical

                            Greece arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ranolazine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparison of Effectiveness of Ranolazine Plus Metoprolol Combination vs. FlecainidE pluS Metoprolol Combinati...

                            Details : Ranolazine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Atrial Fibrillation.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 22, 2017

                            Lead Product(s) : Ranolazine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ELPEN Pharmaceutical

                            Greece arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            ELPEN Pharmaceutical

                            Greece arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Esomeprazole Magnesium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infect...

                            Details : Esomeprazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Helicobacter Infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 09, 2016

                            Lead Product(s) : Esomeprazole Magnesium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ELPEN Pharmaceutical

                            Greece arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            ELPEN Pharmaceutical

                            Greece arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            COlchicine for the Prevention of Post Electrical Cardioversion Recurrence of AF

                            Details : Colchicine is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Atrial Fibrillation.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            October 21, 2015

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ELPEN Pharmaceutical

                            Greece arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            ELPEN Pharmaceutical

                            Greece arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Efzofitimod

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Single Dose Study of the Fluticasone/Salmeterol (500/50 μg) Administered With Elpenhaler® Versus DiskusÃ...

                            Details : Efzofitimod is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Asthma.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 02, 2011

                            Lead Product(s) : Efzofitimod

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth